Wankowicz SAM, Werner L, Orsola A, Novak J, Bowden M, Choueiri TK, de Torres I, Morote J, Freeman GJ, Signoretti S et al..  2017.  Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.. J Urol. 198(4):817-823.

Bailis W, Shyer JA, Chiorazzi M, Flavell RA.  2017.  No Oxygen? No Glucose? No Problem: Fatty Acid Catabolism Enhances Effector CD8 TILs. Cancer Cell. 32(3):280-281.

Li B, Severson E, Pignon J-C, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S et al..  2016.  Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.. Genome Biol. 17(1):174.

Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A et al..  2016.  Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.. Genome Biol. 17(1):231.

Vatakis DN, Koya RC, Nixon CC, Wei L, Kim SG, Avancena P, Bristol G, Baltimore D, Kohn DB, Ribas A et al..  2011.  Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells.. Proc Natl Acad Sci U S A. 108(51):E1408-16.